Table 5.
Study | No. of patients | Initial and following dose | OR (%) | Median TOP and range (months) |
---|---|---|---|---|
Trastuzumab | ||||
Baselga et al. [27] | 105 | 8 mg/kg, 6 mg/kg triweekly | 19 | 3.4 (range 0.6–23.6) |
Cobleigh et al. [26] | 222 | 4 mg/kg, 2 mg/kg weekly | 15 | 3.1 (range 0–≥28) |
Vogel et al. [39] | 114 | 4 mg/kg, 2 mg/kg weekly | 26 | 3.8 (range 3.3–5.3) |
Or 8 mg/kg, 4 mg/kg weekly | ||||
Lapatinib | ||||
Gomez et al. [30] | 69 | 1500 mg once daily | 24 | 4.4 (range 0.5–23) |
Or 500 mg twice daily |
OR: Overall response rate; TOP: Time to progression.
To date, most lapatinib therapies are still in progress and currently being evaluated.